141 related articles for article (PubMed ID: 30221206)
1. Role of secretory clusterin in hepatocarcinogenesis.
Yao M; Fang M; Zheng W; Dong Z; Yao D
Transl Gastroenterol Hepatol; 2018; 3():48. PubMed ID: 30221206
[TBL] [Abstract][Full Text] [Related]
2. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target.
Zheng W; Yao M; Qian Q; Sai W; Qiu L; Yang J; Wu W; Dong Z; Yao D
Oncotarget; 2017 Aug; 8(32):52321-52332. PubMed ID: 28881732
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma.
Zheng W; Yao M; Sai W; Qian Q; Pan L; Qiu L; Huang J; Wu W; Yao D
Tumour Biol; 2016 Jan; 37(1):999-1008. PubMed ID: 26264614
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Oncol Lett; 2018 May; 15(5):7191-7199. PubMed ID: 29731881
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
[TBL] [Abstract][Full Text] [Related]
7. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
8. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
[No Abstract] [Full Text] [Related]
9. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays.
Bi J; Guo AL; Lai YR; Li B; Zhong JM; Wu HQ; Xie Z; He YL; Lv ZL; Lau SH; Wang Q; Huang XH; Zhang LJ; Wen JM; Guan XY
Neoplasma; 2010; 57(3):191-7. PubMed ID: 20353268
[TBL] [Abstract][Full Text] [Related]
11. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
Niu ZH; Wang Y; Chun B; Li CX; Wu L
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1337-44. PubMed ID: 23740447
[TBL] [Abstract][Full Text] [Related]
12. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death.
Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y
Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Zoubeidi A; Chi K; Gleave M
Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
[TBL] [Abstract][Full Text] [Related]
15. The chaperone activity of clusterin is dependent on glycosylation and redox environment.
Rohne P; Prochnow H; Wolf S; Renner B; Koch-Brandt C
Cell Physiol Biochem; 2014; 34(5):1626-39. PubMed ID: 25402950
[TBL] [Abstract][Full Text] [Related]
16. Clusterin and chemoresistance.
Djeu JY; Wei S
Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein J/Clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence.
Antonelou MH; Kriebardis AG; Stamoulis KE; Trougakos IP; Papassideri IS
PLoS One; 2011; 6(10):e26032. PubMed ID: 21998749
[TBL] [Abstract][Full Text] [Related]
18. Secretory clusterin is upregulated in rats with pulmonary arterial hypertension induced by systemic-to-pulmonary shunts and exerts important roles in pulmonary artery smooth muscle cells.
Liu X; Meng L; Li J; Meng J; Teng X; Gu H; Hu S; Wei Y
Acta Physiol (Oxf); 2015 Feb; 213(2):505-18. PubMed ID: 25069740
[TBL] [Abstract][Full Text] [Related]
19. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
20. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
